Table 2.
Clinical features and radiological imaging scores in each treatment group from baseline and 3 months follow up in all patients with rheumatoid arthritis who had a 3-month follow-up visit
| Total (n = 22) | MTX only group (n = 9) | MTX + anti-TNFα group (n = 13) | ||||||
|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Baseline | 3 Months | Changes | p value* | Baseline | 3 Months | Changes | p value* |
| Disease activity | ||||||||
| Swollen joints | 0.7 ± 1.0 | 1.6 ± 1.8 | 0.9 ± 1.8 | 0.184 | 14.5 ± 3.9 | 6.3 ± 4.8 | -8.2 ± 6.6 | <0.001 |
| Tender joints | 0.7 ± 1.1 | 1.0 ± 1.3 | 0.3 ± 1.2 | 0.438 | 9.3 ± 6.2 | 4.4 ± 9.5 | -4.9 ± 9.9 | 0.086 |
| Global assessment of patient | 7.4 ± 15.3 | 16.3 ± 25.7 | 8.9 ± 19.6 | 0.210 | 62.2 ± 16.8 | 41.4 ± 31.2 | -20.8 ± 26.6 | 0.015 |
| Physician | 11.7 ± 10.9 | 14.1 ± 12.6 | 2.4 ± 9.4 | 0.459 | 42.8 ± 10.7 | 26.4 ± 12.1 | -16.4 ± 18.2 | 0.005 |
| ESR unm h) (mm/h) | 18.0 ± 22.3 | 21.0 ± I8.3 | 3.0 ± 10.9 | 0.435 | 32.2 ± 21.9 | 29.7 ± 21.6 | -2.4 ± 12.9 | 0.490 |
| CRP tmg/L) (mg/L) | 2.1 ± 1.1 | 4.6 ± 3.5 | 2.4 ± 2.9 | 0.034 | 21.9 ± 28.1 | 10.4 ± 9.8 | -11.5 ± 22.2 | 0.088 |
| DAS-28-ESR | 1.9 ± 0.9 | 2.6 ± 0.9 | 0.7 ± 1.2 | 0.106 | 5.7 ± 1.1 | 3.8 ± 1.2 | -2.0 ± 0.9 | <0.001 |
| DAS-28-CRP | l.8 ± 0.7 | 2.4 ± 0.8 | 0.6 ± 0.6 | 0.032 | 5.4 ± 0.9 | 3.5 ± 1.0 | -I.7 ± 1.1 | <0.001 |
| HAQ | 0.5 ± 0.7 | 0.7 ± 0.8 | 0.2 ± 0.3 | 0.084 | 1.6 ± 0.7 | 1.0 ± 0.7 | -0.6 ± 0.6 | 0.001 |
| Modified SHARP score | ||||||||
| Total | 4.7 ± 6.0 | NA | NA | 26.1 ± 42.0 | NA | NA | ||
| Erosion | 1.6 ± 2.6 | 13.5 ± 26.8 | ||||||
| JSN | 3.1 ± 4.9 | 12.5 ± 17.0 | ||||||
| RAMRIS score | ||||||||
| JSN | 0.2 ± 0.4 | 0.3 ± 0.7 | 0.1 ± 0.3 | 0.347 | 5.9 ± 8.4 | 5.9 ± 8.5 | 0.0 ± 0.4 | <1.000 |
| Synovitis | 3.2 ± 2.1 | 3.1 ± 2.1 | -0.1 ± 0.9 | 0.598 | 4.9 ± 2.6 | 3.9 ± 2.3 | -l.0 ± 2.1 | 0.126 |
| Bone erosion | 2.6 ± 2.2 | 2.6 ± 2.6 | 0.0 ± 0.9 | <1.000 | 20.5 ± 33.4 | 21.2 ± 33.3 | 0.6 ± 1.2 | 0.171 |
| Bone edema | 4.9 ± 4.0 | 4.9 ± 3.6 | 0.0 ± 1.1 | <1.000 | 9.7 ± 7.8 | 7.1 ± 6.3 | -2.6 ± 3.8 | 0.105 |
MTX methotrexate, TNFa tumor necrosis factor alpha, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS-28 disease activity score 28, HAQ health assessment questionnaire score, JSN joint space narrowing, NA not applicable, RAMRIS Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis-magnetic resonance imaging scoring. *Paired t test